Immutep Ltd (ASX: IMM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immutep Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $439.87 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.19 billion
Earnings per share -0.039
Dividend per share N/A
Year To Date Return 11.59%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Immutep Ltd (ASX: IMM)
    Latest News

    A sad looking scientist sitting and upset about a share price fall.
    Healthcare Shares

    Why did the Immutep share price plummet 31% last month?

    June was a rough one for this ASX biotechnology stock.

    Read more »

    Two staff in a medical research laboratory wearing masks and caps work on their tests, representing the performance of ASX healthcare shares in FY22
    Healthcare Shares

    Here's how ASX healthcare shares performed in FY22

    ASX healthcare shares took a massive plunge from the restart of trade in January.

    Read more »

    Two researchers discussing results of a study with each other.
    Healthcare Shares

    Here's how ASX 200 healthcare shares performed in June

    Healthcare shares were a tad ill in June.

    Read more »

    A businessman presents a company annual report in front of a group seated at a table
    Healthcare Shares

    Own Immutep shares? Here are 3 takeaways from the company's investor update

    Investors were mute to the update.

    Read more »

    A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
    Healthcare Shares

    What's driving the Immutep share price in June?

    Can the ASX healthcare share maintain its momentum this month?

    Read more »

    Rocket powering up and symbolising a rising share price.
    Healthcare Shares

    Why has the Immutep share price rocketed 24% in a month?

    Here's what's been going right for the biotech stock lately.

    Read more »

    Two happy scientists analysing test results in a lab
    Healthcare Shares

    10-baggers? Expert names 2 super-cheap biotech ASX shares

    Biotech and health tech stocks have suffered greatly in recent months. But one fund manager is sticking by 2 particular…

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in

    After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

    Read more »

    four people celebrate with champagne in front of gold 2022 balloons
    Best Shares

    Top ASX shares to buy in January 2022

    Made some new-year's investing resolutions? Here are some expert stock picks to consider inviting to the party.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    3 ASX biotech shares rated as buys in 2022

    We hear the expert opinion of analysts covering the space.

    Read more »

    Man in whit coat after explosion.
    Healthcare Shares

    2 ASX healthcare shares set to explode 70% in 2022: expert

    Biotech and health stocks can fluctuate wildly, but when things go right they can be very rewarding for investors. Here's…

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Here's why the Immutep (ASX:IMM) share price is up today

    Immutep has signed a new agreement on a key antibody product.

    Read more »

    Frequently Asked Questions

    No, Immutep does not pay dividends at this time.

    Immutep Ltd listed on the ASX on 23 June 1988.

    IMM ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Immutep Ltd

    Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.

    IMM Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $0.37 $-0.02 -5.19% 1,118,079 $0.38 $0.39 $0.37
    26 Mar 2024 $0.39 $0.01 2.63% 629,449 $0.39 $0.39 $0.38
    25 Mar 2024 $0.38 $-0.01 -2.60% 356,341 $0.38 $0.39 $0.38
    22 Mar 2024 $0.39 $0.01 2.67% 458,159 $0.38 $0.39 $0.37
    21 Mar 2024 $0.38 $0.01 2.74% 405,002 $0.37 $0.39 $0.37
    20 Mar 2024 $0.37 $-0.01 -2.67% 1,054,151 $0.37 $0.38 $0.36
    19 Mar 2024 $0.38 $0.01 2.74% 1,131,494 $0.36 $0.38 $0.36
    18 Mar 2024 $0.37 $0.00 0.00% 546,264 $0.36 $0.37 $0.36
    15 Mar 2024 $0.37 $-0.02 -5.26% 1,007,684 $0.38 $0.38 $0.36
    14 Mar 2024 $0.38 $0.01 2.67% 973,753 $0.38 $0.38 $0.38
    13 Mar 2024 $0.38 $-0.01 -2.63% 400,836 $0.38 $0.39 $0.38
    12 Mar 2024 $0.38 $-0.02 -5.00% 815,516 $0.39 $0.39 $0.37
    11 Mar 2024 $0.40 $-0.01 -2.44% 1,801,525 $0.42 $0.42 $0.39
    08 Mar 2024 $0.41 $0.01 2.50% 3,636,973 $0.41 $0.42 $0.41
    07 Mar 2024 $0.40 $0.03 8.11% 6,309,634 $0.40 $0.41 $0.39
    06 Mar 2024 $0.37 $-0.01 -2.63% 2,580,727 $0.38 $0.39 $0.36
    05 Mar 2024 $0.38 $0.02 5.56% 2,323,724 $0.36 $0.41 $0.36
    04 Mar 2024 $0.36 $0.01 2.86% 1,827,125 $0.36 $0.36 $0.35
    01 Mar 2024 $0.35 $-0.02 -5.48% 163,787 $0.37 $0.37 $0.35
    29 Feb 2024 $0.37 $0.01 2.82% 887,175 $0.35 $0.37 $0.35
    28 Feb 2024 $0.36 $0.01 2.90% 600,322 $0.34 $0.36 $0.34
    27 Feb 2024 $0.35 $0.02 6.15% 324,044 $0.35 $0.35 $0.33

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 Nov 2023 Russell Howard Issued 178,356 $52,615
    Director remuneration. 404,770 Director Performance Rights
    23 Nov 2023 Lis (Elisabeth) Boyce Issued 589,955 $174,036
    Director remuneration. 589,955 Director Performance
    Rights
    03 Oct 2023 Pete Meyers Issued 500,000 $142,500
    Conversion of securities.
    03 Oct 2023 Pete Meyers Exercise 500,000 $142,500
    Conversion of securities. 1,166,667 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Russell J Howard Non-Executive ChairmanNon-Executive Director May 2013
    Dr Howard is an Australian scientist, executive manager, and entrepreneur. He was a pioneer in molecular parasitology and commercialisation of DNA Shuffling. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc.
    Ms Anne L Anderson Non-Executive Director Feb 2024
    Ms Anderson has board and leadership experience serving Australian and international companies. Anne currently serves as NED of leading Australian wealth manager, BTFM and was previously on the Board of an unlisted subsidiary of Ingenia Communities Group. She currently holds a portfolio of advisory and committee roles including as a Member of the Advisory Board to The Treasury (Australia), Member of the EnergyCo Transmission Acceleration Facility Investment Committee for the NSW Treasury, Advisor to the REST Board Investment Committee, Independent Member of the Minderoo Foundation and E&P Financial Group Investment Committees and Member of the ASIC Consultative Panel. Prior to her NED and committee roles, she completed an executive career of more than 35 years spanning the energy and global financial services sectors.
    Mr Pete A Meyers Non-Executive Deputy ChairmanNon-Executive Director Feb 2014
    Mr Meyers is the Chief Financial Officer of Slayback Pharma LLC. Prior to joining Slayback, Mr Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC.
    Mr Marc Voigt Chief Financial OfficerChief Executive OfficerExecutive Director May 2012
    Mr Voigt has more than 21 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Immutep 's Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments.
    Professor Frederic Triebel Executive Director Sep 2022
    Professor Triebel founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer of Immutep following the Company's acquisition of Immutep S.A in December 2014. While working at IGR as an oncologist, he was also a Professor in Immunology at Paris University and a Director of an INSERM Unit from 1991 to 1996.
    Ms Lis (Elisabeth) Boyce Non-Executive Director Apr 2023
    Ms Boyce is corporate lawyer. She is currently a partner at Piper Alderman and was previously a partner at Dentons, having been at DibbsBarker for nearly 30 years. She has involvement in the Life Sciences and Healthcare sectors and is currently deputy chair of AusBiotechs AusMedtech Advisory Group and a member of AusBiotechs NSW Leadership Committee.
    Ms Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
    -
    Ms Indira Naidu Joint Company Secretary Jan 2021
    -
    Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
    -
    Indira Naidu Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 386,571,289 32.56%
    J P Morgan Nominees Australia Pty Limited 165,050,307 13.90%
    Citicorp Nominees Pty Limited 81,121,672 6.83%
    Tripp Investments Pty Ltd <Tripp Investment A/C> 70,936,692 5.97%
    Tekkorp Holdings Llc 39,284,648 3.31%
    National Nominees Limited 11,243,351 0.95%
    Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 11,191,695 0.94%
    Edinburgh Park Stud Pty Ltd 8,653,764 0.73%
    Todd Cameron Buckingham 7,692,440 0.65%
    Rbw Nominees Pty Ltd <Rbw Discretionary A/C> 7,584,327 0.64%
    Mr David Mark Rocci 6,862,905 0.58%
    Bridgetrack Investments Pty Ltd 6,484,177 0.55%
    Revilo Corporate Pty Ltd <Revilo Corporate A/C> 6,053,816 0.51%
    Tjct Pty Limited <Buckingham Super Fund A/C> 4,978,772 0.42%
    P G Binet (No 5) Pty Ltd 4,799,700 0.40%
    J & M Hunter Investments Pty Ltd <J & M Hunter Investment A/C> 4,114,620 0.35%
    Ada Services (Nsw) Pty Ltd <Ada Services Super Fund A/C> 3,800,000 0.32%
    Hawksburn Capital Pte Ltd <Methuselah Strategic Fnd A/C> 3,267,305 0.28%
    Christopher Robert Begg 3,074,592 0.26%
    Mr Karl Alexander Begg 2,774,395 0.23%

    Profile

    since

    Note